Saturday, 31 October 2026European Markets

REXEL And GLINTT Have A High Dividend Yield And Return On Equity In The Technology Sector.

Loading stream...

(vianews) - rexel (rxl.pa) is among this list of stock assets with the highest dividend rate and return on equity on the technology sector.

financial asset price forward dividend yield return on equity
rexel (rxl.pa) €25.03 4.95% 14.33%
glintt (glint.ls) €0.52 4.78% 5.11%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. rexel (rxl.pa)

4.95% forward dividend yield and 14.33% return on equity

rexel s.a., together with its subsidiaries, engages in distribution of low and ultra-low voltage electrical products and services for the residential, commercial, and industrial markets in france, europe, north america, and asia-pacific. the company offers smart cameras, sensors, controllers, and monitoring software; light sources, lights, and control switches; climate control products, including heat pumps, air conditioning, and water heaters; fire alarms, surveillance equipment, access controls devices, and emergency lightings; and connection cables, and switches and routers, as well as enclosures, mounts, and racks. it also provides solar modules and inverters; connected lighting, intelligent home system, home control touch screen, and smart thermostat products; residential chargers, commercial stations, and charging cables for electric vehicles; electric motors, variable speed drives, programmable logic controllers, and computers and operator interface; and fastening systems, electrical power and control, and valves and instrumentation products. the company offers products, services, and solutions in the fields of technical supply, automation, and energy management related to the construction, renovation, maintenance, and production. it operates in 21 countries. the company was founded in 1967 and is headquartered in paris, france.

earnings per share

as for profitability, rexel has a trailing twelve months eps of €2.57.

pe ratio

rexel has a trailing twelve months price to earnings ratio of 9.74. meaning, the purchaser of the share is investing €9.74 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.33%.

more news about rexel.

2. glintt (glint.ls)

4.78% forward dividend yield and 5.11% return on equity

glintt - global intelligent technologies, s.a. provides it consulting services for banking, insurance, public administration, and utilities sectors in portugal, spain, and angola. it operates through two segments: health and other markets. the company engages in the sale of equipment, furniture, consumables, and robotics solutions; development of architectural projects; and design and conception of lay-out and image for pharmacies, training, equipment maintenance, and consultancy projects. it licenses proprietary software solutions for healthcare providers, such as clinics, hospitals, pharmacies, and other bodies of the ministry of health; and develops, implements, and maintains software services for the health sector. in addition, the company implements erps, integrates internet systems, and develops tailor-made applications services. further, the company develops, implements, and integrates partner platforms with emphasis on the bpm, erp, bi and mobility solutions; and integrates it infrastructures, as well as support for networking, security, storage systems, and database management. glintt - global intelligent technologies, s.a. was incorporated in 1995 and is based in sintra, portugal. glintt - global intelligent technologies, s.a. operates as a subsidiary of farminveste - investimentos, participações e gestão s.a.

earnings per share

as for profitability, glintt has a trailing twelve months eps of €0.05.

pe ratio

glintt has a trailing twelve months price to earnings ratio of 10.3. meaning, the purchaser of the share is investing €10.3 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.11%.

volume

today's last reported volume for glintt is 23678 which is 66.13% above its average volume of 14252.

revenue growth

year-on-year quarterly revenue growth grew by 7.7%, now sitting on 117.39m for the twelve trailing months.

volatility

glintt's last week, last month's, and last quarter's current intraday variation average was 1.54%, 1.01%, and 2.42%.

glintt's highest amplitude of average volatility was 3.49% (last week), 2.68% (last month), and 2.42% (last quarter).

more news about glintt.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com